BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

649 related articles for article (PubMed ID: 31088509)

  • 1. Rituximab in relapsing and de novo MPO ANCA-associated vasculitis with severe renal involvement: a case series.
    Caroti L; Cirami CL; Di Maria L; Larti A; Carta P; Dervishi E; Farsetti S; Tsalouchos A; Novelli L; Minetti EE
    BMC Nephrol; 2019 May; 20(1):162. PubMed ID: 31088509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab for treatment of severe renal disease in ANCA associated vasculitis.
    Geetha D; Hruskova Z; Segelmark M; Hogan J; Morgan MD; Cavero T; Eriksson P; Seo P; Manno RL; Dale J; Harper L; Tesar V; Jayne DR
    J Nephrol; 2016 Apr; 29(2):195-201. PubMed ID: 25986390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab for remission induction in elderly patients with ANCA-associated vasculitis.
    Timlin H; Lee SM; Manno RL; Seo P; Geetha D
    Semin Arthritis Rheum; 2015 Aug; 45(1):67-9. PubMed ID: 25796088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Rituximab and Plasma Exchange in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis with Severe Kidney Disease.
    Casal Moura M; Irazabal MV; Eirin A; Zand L; Sethi S; Borah BJ; Winters JL; Moriarty JP; Cartin-Ceba R; Berti A; Baqir M; Thompson GE; Makol A; Warrington KJ; Thao V; Specks U; Fervenza FC
    J Am Soc Nephrol; 2020 Nov; 31(11):2688-2704. PubMed ID: 32826324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential Therapy for Remission Induction in Severe Antineutrophil Cytoplasmic Autoantibody-Associated Glomerulonephritis.
    Kant S; Habbach A; Gapud EJ; Manno RL; Gattu R; Seo P; Geetha D
    Am J Nephrol; 2019; 50(5):386-391. PubMed ID: 31593967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of severe renal disease in ANCA positive and negative small vessel vasculitis with rituximab.
    Shah S; Hruskova Z; Segelmark M; Morgan MD; Hogan J; Lee SK; Dale J; Harper L; Tesar V; Jayne DR; Geetha D
    Am J Nephrol; 2015; 41(4-5):296-301. PubMed ID: 26044574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement.
    Geetha D; Specks U; Stone JH; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Fessler BJ; Ding L; Tchao NK; Ikle D; Jepson B; Brunetta P; Fervenza FC;
    J Am Soc Nephrol; 2015 Apr; 26(4):976-85. PubMed ID: 25381429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of protein A immunoadsorption and therapeutic plasma exchange in ANCA-associated vasculitis with severe renal involvement: a retrospective study.
    Liu X; Xia M; Liu D; Liu H; Tang C; Chen G; Liu Y; Yuan F; Liu H
    Ann Med; 2023 Dec; 55(1):2230875. PubMed ID: 37452682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of remission induction therapy for ANCA-associated vasculitis in the elderly.
    Aqeel F; Xu L; Salas A; Wen Y; Eid SM; Geetha D
    Clin Rheumatol; 2023 Sep; 42(9):2427-2435. PubMed ID: 37225927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type.
    Unizony S; Villarreal M; Miloslavsky EM; Lu N; Merkel PA; Spiera R; Seo P; Langford CA; Hoffman GS; Kallenberg CM; St Clair EW; Ikle D; Tchao NK; Ding L; Brunetta P; Choi HK; Monach PA; Fervenza F; Stone JH; Specks U;
    Ann Rheum Dis; 2016 Jun; 75(6):1166-9. PubMed ID: 26621483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study.
    Jayne D; Blockmans D; Luqmani R; Moiseev S; Ji B; Green Y; Hall L; Roth D; Henderson RB; Merkel PA;
    Arthritis Rheumatol; 2019 Jun; 71(6):952-963. PubMed ID: 30666823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis.
    McAdoo SP; Medjeral-Thomas N; Gopaluni S; Tanna A; Mansfield N; Galliford J; Griffith M; Levy J; Cairns TD; Jayne D; Salama AD; Pusey CD
    Nephrol Dial Transplant; 2019 Jan; 34(1):63-73. PubMed ID: 29462348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis.
    Pepper RJ; McAdoo SP; Moran SM; Kelly D; Scott J; Hamour S; Burns A; Griffith M; Galliford J; Levy JB; Cairns TD; Gopaluni S; Jones RB; Jayne D; Little MA; Pusey CD; Salama AD
    Rheumatology (Oxford); 2019 Feb; 58(2):260-268. PubMed ID: 30239910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treating Patients With ANCA-Associated Vasculitis and Very Severe Renal Injury With an Intensified B Cell Depletion Therapy: Comparison With a Control Cohort Receiving a Conventional Therapy.
    Roccatello D; Sciascia S; Murgia S; Quattrocchio G; Ferro M; De Simone E; Naretto C; Barreca A; Sammartino A; Rossi D; Fenoglio R
    Front Immunol; 2022; 13():777134. PubMed ID: 35401565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunoadsorption Improves Remission Rates of Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis and Severe Kidney Involvement.
    Chu X; Hong Y; Wang Y; Yu C; Wang L; Tong H; Yan J; Zhang Z; Xu G; Yao Y; Zeng R
    Am J Nephrol; 2021; 52(12):899-908. PubMed ID: 34875652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab Versus Cyclophosphamide for Central Nervous System Involvement of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Case Series.
    Krishna R; De Giacomi F; Kumar N; Kalina P; Specks U; Baqir M
    J Clin Rheumatol; 2021 Mar; 27(2):64-72. PubMed ID: 31567753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Effectiveness of Rituximab- Versus Cyclophosphamide-Based Remission Induction Strategies in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis for the Risk of Kidney Failure and Mortality.
    Wallace ZS; Fu X; Cook C; Ahola C; Williams Z; Doliner B; Hanberg JS; Stone JH; Zhang Y; Choi HK
    Arthritis Rheumatol; 2023 Sep; 75(9):1599-1607. PubMed ID: 37011036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2).
    Charles P; Terrier B; Perrodeau É; Cohen P; Faguer S; Huart A; Hamidou M; Agard C; Bonnotte B; Samson M; Karras A; Jourde-Chiche N; Lifermann F; Gobert P; Hanrotel-Saliou C; Godmer P; Martin-Silva N; Pugnet G; Matignon M; Aumaitre O; Viallard JF; Maurier F; Meaux-Ruault N; Rivière S; Sibilia J; Puéchal X; Ravaud P; Mouthon L; Guillevin L;
    Ann Rheum Dis; 2018 Aug; 77(8):1143-1149. PubMed ID: 29695500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ANCA-associated vasculitis in scleroderma: A renal perspective
.
    Kant S; Shah AA; Hummers LK; Wigley FM; Geetha D
    Clin Nephrol; 2018 Dec; 90(6):413-418. PubMed ID: 30106367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab in relapsing or refractory ANCA-associated vasculitis: a case series of 16 patients.
    Wendt M; Gunnarsson I; Bratt J; Bruchfeld A
    Scand J Rheumatol; 2012 Mar; 41(2):116-9. PubMed ID: 22118245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.